GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (FRA:ZA8) » Definitions » Institutional Ownership

Zymeworks (FRA:ZA8) Institutional Ownership : 30.71% (As of Jun. 06, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Zymeworks Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Zymeworks's institutional ownership is 30.71%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Zymeworks's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Zymeworks's Float Percentage Of Total Shares Outstanding is 88.05%.


Zymeworks Institutional Ownership Historical Data

The historical data trend for Zymeworks's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zymeworks Institutional Ownership Chart

Zymeworks Historical Data

The historical data trend for Zymeworks can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 32.42 33.47 30.68 29.25 30.71 30.76 30.36 30.87 30.74 30.71

Zymeworks Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Zymeworks (FRA:ZA8) Business Description

Traded in Other Exchanges
Address
108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Zymeworks (FRA:ZA8) Headlines

No Headlines